A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children

Neurology

Volumn 53, Issue 8, 1999, Pages 1724-1731

  Duchowny, M ^a   Pellock, J M ^b   Graf, W D ^c   Billard, C ^d   Gilman, J ^a   Casale, E ^e   Womble, G ^e   Risner, M ^e   Manasco, P ^d  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d Centre de Pediatrie Clocheville   (France)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Epilepsy; Lamotrigine; Partial seizures; Pediatric

Indexed keywords

ANTICONVULSIVE AGENT; LAMOTRIGINE; VALPROIC ACID;

ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; ATAXIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOCAL EPILEPSY; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PEDIATRICS; PRIORITY JOURNAL; RASH; TREMOR; UNITED STATES; VERTIGO;

EID: 0033544351     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.8.1724     Document Type: Article

References (35)

1. Sander JWAS, Shorvon SD. Incidence and prevalence studies in epilepsy and their methodological problems: a review. J Neurol Neurosurg Psychiatry 1987;50:829-839.
2. Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994;35:S1-S6.
3. Leviton A, Cowan LD. Epidemiology of seizure disorders in children. Neuroepidemiology 1982;1:40-83.
4. Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Safety 1996; 15:378-393.
5. Troupin AS. Dose-related adverse effects of anticonvulsants. Drug Safety 1996;14:299-328.
6. Phenytoin (Dilantin®) product information. Morris Plains, NJ: Parke-Davis, 1996.
7. Carbamazepine (Tegretol®) product information. East Hanover, NJ: Novartis Pharmaceuticals, 1997.
8. Divalproex sodium (Depakote®) product information. North Chicago, IL: Abbott Laboratories, 1997.
9. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-176.
10. Motte J, Trevathan E, Arvidsson JFV et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997;337:1807-1812.
11. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo controlled crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56:448-453.
12. Brodie MJ, Richens A, Yuen AWC for the UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and Carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-479.
13. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-151.
14. Leach MJ, Marden CM, Miller AA. Pharmacological studies of lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27:490-497.
15. + channels in rat hippocampal neurones. Pflugers Arch 1995;430:437-446.
16. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-2291.
17. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-1025.
18. Besag FMC, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:991-997.
19. Schlumberger E, Chavez F, Placios L, Rey E, Pajet N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-365.
20. Buchanan N. The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure 1995;4:233-236.
21. Buoni S, Grosso S, Fois A. Lamotrigine treatment in childhood drug resistant epilepsy. J Child Neurol 1998;13:163-167.
22. Besag FMC, Dulac O, Alving J, et al. Long-term safety and efficacy of lamotrigine (Lamictal®) in paediatric patients with epilepsy. Seizure 1997;6:51-56.
23. Schapel G, Wallace SJ, Gordon GS. A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy. Seizure 1997;6:479-483.
24. Frank LM, Enlow T, Holmes GL, et al. Lamictal® (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:973-979.
25. Eriksson AS, Nergardh, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998;39:495-501.
26. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998;18:281-296.
27. Fogh K, Mai J. Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal®). Seizure 1997;6:63-65.
28. Chaffin JJ, Davis SM. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother 1997;31:720-723.
29. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, Carbamazepine or sodium valproate: a record linkage study. Neurology 1997;49:542-546.
30. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
31. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol 1990;126:43-47.
32. Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996;37:208-212.
33. Sachs B, Rönnau AC, von Schmiedeberg S, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997;195:60-64.
34. Iannetti P, Raucci U, Zuccaro P, Pacifici R. Lamotrigine hypersensitivity in childhood epilepsy. Epilepsia 1998;39:502-507.
35. Lamotrigine (Lamictal®) product information. Research Triangle Park, NC: Glaxo Wellcome, 1998.